| Literature DB >> 35392892 |
Lodovico Patrizi1, Carlo Ticconi2, Barbara Borelli1, Susanna Finocchiaro3, Carlo Chiaramonte4, Francesco Sesti1, Alessandro Mauriello3, Caterina Exacoustos1, Luisa Casadei1.
Abstract
BACKGROUND: The overall clinical significance of the finding of endometrial abnormalities in predicting premalignant/malignant endometrial lesions is still incompletely determined. For this reason the management, surgical or expectant, of women in which an endometrial abnormality has been detected is debated.Entities:
Keywords: AUB; Endometrial atypia and cancer; Endometrial polyps; Hysteroscopy; Menopause; Transvaginal ultrasonography
Mesh:
Year: 2022 PMID: 35392892 PMCID: PMC8991822 DOI: 10.1186/s12905-022-01682-5
Source DB: PubMed Journal: BMC Womens Health ISSN: 1472-6874 Impact factor: 2.809
Major clinical characteristics of study women according to their menopausal status
| Premenopause (n = 403 women) | Postmenopause (n = 617 women) | ||
|---|---|---|---|
| Age (years) | 43 ± 6.85 | 63.6 ± 9.42 | t = − 37.84 [95% C.I.: − 21.60 to − 19.59] |
| BMI (kg/m2) | 27.5 ± 5.24 | 28.9 ± 7.08 | t = − 3.40 [95% C.I.: − 2.15 to − 0.64] |
| < 25 | 266 (66%) | 184 (29.82%) | χ2 = 129.30, [95% C.I.: 30.13–41.83] |
| 25–29.9 | 87 (21.59%) | 225 (36.47%) | χ2 = 25.17 [95% C.I.: 9.15–20.19] |
| 30–39.9 | 46 (11.41%) | 180 (29.17%) | χ2 = 44.54, [95% C.I.: 12.86–22.37] |
| 4 (0.99%) | 28 (4.54%) | χ2 = 10.09, [95% C.I.: 1.48–5.58] | |
| Systemic hypertension | 38 (9.43%) | 310 (50.24) | χ2 = 180.45, [95% C.I.: 35.70–45.45] |
| Diabetes mellitus | 12 (2.98%) | 73 (11.83) | χ2 = 24.97, [95% C.I.: 5.68–11.91] |
| AUB | 233 (57.82%) | 183 (29.66%) | χ2 = 79.96, [95% C.I.: 22.02–34.02] |
| Use of Tamoxifen | 2 (0.5%) | 57 (9.24%) | χ2 = 34.12, [95% C.I.: 6.32–11.30] |
| Present | 239 (59.31%) | 173 (28.04%) | χ2 = 98.90, [95% C.I.: 25.17–37.06] |
| Absent | 164 (40.69%) | 444 (71.96%) | χ2 = 98.93, [95% C.I.: 25.17–37.06] |
| Yes | 349 (86.6%) | 500 (81.04%) | χ2 = 5.39, [95% C.I.: 0.88–9.94] |
| No | 54 (13.4%) | 117 (18.96%) | χ2 = 5.39, [95% C.I.: 0.88–9.99] |
BMI body mass index, AUB = Abnormal uterine bleeding. Values are shown as mean ± SD, or n (%)
t = Student’s t test; χ2 = Chi-square test
Histopathologic diagnoses in the study women stratified by menopausal status
| Type of lesion | Premenopausal (n = 403 women) | Postmenopausal (n = 617 women) | |
|---|---|---|---|
| Benign | 399 (90.01%) | 587 (95.14%) | O.R. [95% C.I.] = 5.098 [1.782–14.582], |
| Premalignant/malignant | 4 (0.99%) | 30 (4.46%) | |
| Endometrial cystic-glandular atrophy | 2 (0.50%) | 10 (1.62%) | χ2 = 2.65, [95% C.I.: − 0.37 to 2.50] |
| Endometrium with dysfunctional proliferative disorders | 19 (4.71%) | 3 (0.49%) | χ2 = 20.54, [95% C.I.: 2.30–6.77] |
| Normal endometrium | 51 (12.66%) | 4 (0.65%) | χ2 = 68.82, [95% C.I.: 8.94–15.63] |
| Endometrial polyp | 312 (77.42%) | 540 (87.52%) | χ2 = 18.05, [95% C.I.: 5.34–-15.03] |
| Other benign lesions* | 9 (2.23%) | 20 (3.24%) | χ2 = 0.90, [95% C.I.: − 1.24 to 3.01] |
| Simple glandular hyperplasia | 6 (1.48%) | 9 (1.46%) | χ2 = 0.001, [95% C.I.: − 1.49 to 1.87] |
| Complex glandular hyperplasia without atypia | 0 | 1 (0.16%) | χ2 = 0.63, [95% C.I.: − 0.79 to 0.90] |
| Complex endometrial hyperplasia with atypia | 4 (0.99%) | 18 (2.91%) | χ2 = 4.26, [95% C.I.: 0.05–3.67] |
| Endometrial cancer | 0 | 12 (1.94%) | χ2 = 7.90, [95% C.I.: 0.68–3.36] |
Values are shown as n (%); * submucous myoma, polyp of the cervical canal
Association between the clinical characteristics of study women and the types (benign and premalignant/malignant) of endometrial lesions
| Clinical characteristics of study women | Benign lesions (n = 986 women) | Premalignant and malignant lesions (n = 34 women) | Univariate analysis | ||
|---|---|---|---|---|---|
| Rank | Significance | ||||
| Age (years) | 55.27 ± 13.25 | 61.24 ± 9.69 | * t = − 2.60, [95% C.I.: − 10.47 to − 1.46], | 8 | |
| BMI (kg/m2) | 26.89 ± 6.53 | 34.24 ± 10.24 | * t = − 6.30, [95% C.I.: − 9.63 to − 5.06], | 1 | |
| < 25 | 442 (44.83%) | 10 (29.41%) | O.R. = 0.51 [95% C.I.: 0.24–1.08], | 13 | |
| 25–29.9 | 302 (30.63%) | 9 (26.47%) | O.R. = 0.81 [95% C.I.: 0.37–1.76], | 21 | |
| 30–39.9 | 214 (21.7%) | 11 (32.35%) | O.R. = 1.72 [95% C.I.: 0.82–3.59], | 15 | |
| 28 (2.84%) | 4 (11.76%) | O.R. = 4.56 [95% C.I.: 1.50–13.82], | 9 | ||
| Premenopause | 399 (40.47%) | 4 (11.76%) | O.R. = 0.19 [95% C.I.:0.06–0.56], | 7 | |
| Postmenopause | 587 (59.53%) | 30 (88.24%) | O.R. = 5.09 [95% C.I.:1.78–14.58], | 5 | |
| Systemic hypertension | 329 (33.37%) | 19 (55.88%) | O.R. = 2.52 [95% C.I.:1.26–5.04], | 10 | |
| Diabetes mellitus | 77 (7.81%) | 8 (23.53%) | O.R. = 3.63 [95% C.I.:1.59–8.29], | 6 | |
| Use of tamoxifen | 59 (5.98%) | 0 (0%) | O.R. = 0.22 [95% C.I.: 0.01–3.73], | 19 | |
| AUB in premenopause | 230/233 (98.71%) | 3/233 (1.29%) | O.R. for women with AUB of having premalignant/malignant lesions: 2.20 [95% C.I.: 0.22–21.37], | 14 | |
| No AUB in premenopause | 169/170 (99.4%) | 1/170 (0.6%) | |||
| AUB in postmenopause | 163/183 (89.07%) | 20/183 (10.93%) | O.R. for women with AUB of having premalignant/malignant lesions: 5.20 [95% C.I.: 2.38 – 11.35], | 2 | |
| No AUB in postmenopause | 424/434 (97.7%) | 10/434 (2.3%) | |||
| Women who underwent the procedure | 986 (100%) | 34 (100%) | O.R. = n.d | ||
| Thickened endometrium with respect to the age or phase of the menstrual cycle | 607 (61.56%) | 27 (79.41%) | O.R. = 2.40 [95% C.I.:1.03–5.58], | 11 | |
| Women with endometrial polyps detected at TVS and confirmed histologically | 468 (47.46%) | 12 (35.29%) | O.R. = 0.60 [95% C.I.:0.29–1.23], | 16 | |
| Women who underwent the procedure | 820 (83.16%) | 29 (85.29%) | O.R. = 1.17 [95% C.I.:0.44–3.07], | 22 | |
| Endometrial polyp(s) diagnosed at hysteroscopy | 758/820 (92.43%) | 26/29 (89.65%) | O.R. = 0.70 [95% C.I.:0.20–2.40], | 20 | |
| Thickened endometrium with respect to the age or phase of the menstrual cycle | 257/820 (31.34%) | 12/29 (41.38%) | O.R. = 1.54 [95% C.I.:0.72–3.28], | 18 | |
| Multiple endometrial polyps | 198/820 (24.14%) | 10/29 (34.48%) | O.R. = 1.65 [95% C.I.:0.75–3.61], | 17 | |
| Atypical aspect of endometrial polyps | 7/903 (0.78%) ** | 10/33 (30.3%) *** | O.R. = 55.65 [95% C.I.:19.45–159.16], | 4 | |
| Mean polyp size (mm) | 9.27 ± 3.98 | 12.68 ± 7.29 | * t = − 4.73, [95% C.I.: − 4.82 to − 1.99], | 3 | |
| Mean number of endometrial polyps/woman | 1.1 ± 0.34° | 1.0 ± 0.1°° | *t = -1.71, [95% C.I.: − 0.21 to 0.01], | 12 | |
Values are shown either as mean ± SD or n (%); n.d. = not determined; NS = not significant;*Student’s t test; ** Value referred to the total number of polyps examined (n = 903);*** Value referred to the total number of polyps examined (n = 33); °n women = 758; °° n women = 26